PERSERIS™ (Risperidone): Once-Monthly Injectable.

FDA approved the first once monthly long acting injectable form of Risperidone: PERSERIS™ (in July 2018).

 

INDICATION: 

  • Schizophrenia in adults.


DOSAGE:

  • 90 mg and 120 mg. 

  • Establish tolerability with oral risperidone first.

  • Supplementation with oral risperidone is not recommended.

  • Do not administer more than one dose (90 mg or 120 mg total) per month.


ADMINISTRATION:

  • Administered as an abdominal subcutaneous injection only.

  • Do not administer by any other route.

  • Failure to fully mix the medication could result in incorrect dosage.

  • Allow package to come to room temperature for at least 15 minutes prior to preparation.


DOSE CONVERSION:

  • PERSERIS 90 mg = 3 mg/day oral risperidone.

  • PERSERIS 120 mg = 4 mg/day oral risperidone.

  • Patients who are on stable oral risperidone doses < 3 mg/day or > 4 mg/day may not be candidates for PERSERIS.


DOSE ADJUSTMENT:

  • INITIATE AT LOW DOSE OF 90 MG: for patient also taking strong CYP2D6 Inhibitors (fluoxetine or paroxetine).

  • INITIATE AT HIGH DOSE OF 120 MG: for patient also taking strong CYP3A4 Inducers (carbamazepine).


SOURCE:

Please do post your questions or comments below. 


Dr. Harvinder Singh, M.D. (Admin)


Enroll in our online course to have access to all important clinically relevant psychiatry topics in one place.


Related Articles